MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.020
-0.020
-1.92%
After Hours: 1.030 +0.01 +0.98% 16:55 04/08 EDT
OPEN
1.050
PREV CLOSE
1.040
HIGH
1.093
LOW
0.9901
VOLUME
398.49K
TURNOVER
--
52 WEEK HIGH
4.420
52 WEEK LOW
0.8214
MARKET CAP
70.32M
P/E (TTM)
-0.3527
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ABUS stock price target is 4.667 with a high estimate of 10.00 and a low estimate of 1.000.

EPS

ABUS News

More
  • Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
  • Zacks · 03/31 13:47
  • The Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Have Been Trimming Their Sales Forecasts
  • Simply Wall St. · 03/31 11:16
  • Arbutus reports positive preliminary results from early-stage AB-729 trial
  • seekingalpha · 03/27 16:14
  • The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance
  • Benzinga · 03/27 13:02

Industry

Pharmaceuticals
+2.77%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About ABUS

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.
More

Webull offers kinds of Arbutus Biopharma Corp stock information, including NASDAQ:ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions.